Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole prophylaxis for prevention of influenza-associated aspergillosis in critically ill patients
2017-003270-14Phase 4Completed
- Sponsor
- UZ Leuven
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of posaconazole in aspergillosis and invasive aspergillosis (IA) (2 arms), sponsored by UZ Leuven. Primary endpoint: Incidence of influenza-associated aspergillosis at ICU discharge. Started Sep 2017; status: completed.
02
Drugs
posaconazole
03
Conditions
aspergillosisinvasive aspergillosis (IA)
Beyond the preview
Go deeper on 2017-003270-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003270-14.